PDF(Pubmed)
Abstract：
UNASSIGNED: Immunoinflammatory response can participate in the development of cancer. To investigate the relationship between pretreatment systemic immune inflammatory response index (SII), systemic inflammatory response index (SIRI), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR) and lymph node metastasis in patients with papillary thyroid carcinoma (PTC).
UNASSIGNED: A retrospective analysis was performed on 547 PTC patients treated in Meizhou People\'s Hospital from January 2018 to December 2021. Clinicopathological data were collected, including gender, age, Hashimoto\'s thyroiditis, maximum tumor diameter, extra-membrane infiltration, disease stage, BRAF V600E mutation, pretreatment inflammatory index levels, and lymph node metastasis. The optimal cutoff values of SII, SIRI, NLR, PLR and LMR were calculated by receiver operating characteristic (ROC) curve, and the relationship between inflammatory indexes and other clinicopathological features and lymph node metastasis was analyzed.
UNASSIGNED: There were 303 (55.4%) PTC patients with lymph node metastasis. The levels of SII, SIRI, NLR, and PLR in patients with lymph node metastasis were significantly higher than those in patients without lymph node metastasis, while the levels of LMR were significantly lower than those in patients without lymph node metastasis (all p<0.05). When lymph node metastasis was taken as the endpoint, the critical value of SII was 625.375, the SIRI cutoff value was 0.705, the NLR cutoff value was 1.915 (all area under the ROC curve >0.6). The results of regression logistic analysis showed that age <55 years old (OR: 1.626, 95% CI: 1.009-2.623, p=0.046), maximum tumor diameter >1cm (OR: 2.681, 95% CI: 1.819-3.952, p<0.001), BRAF V600E mutation (OR: 2.709, 95% CI: 1.542-4.759, p=0.001), SII positive (≥625.375/<625.375, OR: 2.663, 95% CI: 1.560-4.546, p<0.001), and NLR positive (≥1.915/<1.915, OR: 1.808, 95% CI: 1.118-2.923, p=0.016) were independent risk factors for lymph node metastasis of PTC.
UNASSIGNED: Age <55 years old, maximum tumor diameter >1cm, BRAF V600E mutation, SII positive, and NLR positive were independent risk factors for lymph node metastasis in PTC.
UNASSIGNED: A retrospective analysis was performed on 547 PTC patients treated in Meizhou People\'s Hospital from January 2018 to December 2021. Clinicopathological data were collected, including gender, age, Hashimoto\'s thyroiditis, maximum tumor diameter, extra-membrane infiltration, disease stage, BRAF V600E mutation, pretreatment inflammatory index levels, and lymph node metastasis. The optimal cutoff values of SII, SIRI, NLR, PLR and LMR were calculated by receiver operating characteristic (ROC) curve, and the relationship between inflammatory indexes and other clinicopathological features and lymph node metastasis was analyzed.
UNASSIGNED: There were 303 (55.4%) PTC patients with lymph node metastasis. The levels of SII, SIRI, NLR, and PLR in patients with lymph node metastasis were significantly higher than those in patients without lymph node metastasis, while the levels of LMR were significantly lower than those in patients without lymph node metastasis (all p<0.05). When lymph node metastasis was taken as the endpoint, the critical value of SII was 625.375, the SIRI cutoff value was 0.705, the NLR cutoff value was 1.915 (all area under the ROC curve >0.6). The results of regression logistic analysis showed that age <55 years old (OR: 1.626, 95% CI: 1.009-2.623, p=0.046), maximum tumor diameter >1cm (OR: 2.681, 95% CI: 1.819-3.952, p<0.001), BRAF V600E mutation (OR: 2.709, 95% CI: 1.542-4.759, p=0.001), SII positive (≥625.375/<625.375, OR: 2.663, 95% CI: 1.560-4.546, p<0.001), and NLR positive (≥1.915/<1.915, OR: 1.808, 95% CI: 1.118-2.923, p=0.016) were independent risk factors for lymph node metastasis of PTC.
UNASSIGNED: Age <55 years old, maximum tumor diameter >1cm, BRAF V600E mutation, SII positive, and NLR positive were independent risk factors for lymph node metastasis in PTC.
摘要：
■免疫炎症反应可参与癌症的发展。探讨治疗前全身免疫炎症反应指数(SII)与治疗前,全身炎症反应指数（SIRI），中性粒细胞与淋巴细胞比率（NLR），血小板与淋巴细胞比率（PLR），甲状腺乳头状癌（PTC）患者的淋巴细胞与单核细胞比率（LMR）和淋巴结转移。
■回顾性分析2018年1月至2021年12月梅州市人民医院收治的547例PTC患者。收集临床病理资料,包括性别,年龄,桥本甲状腺炎,肿瘤最大直径,膜外渗透,疾病阶段,BRAFV600E突变,治疗前炎症指数水平，淋巴结转移。SII的最佳截止值，SIRI,NLR,通过受试者工作特征（ROC）曲线计算PLR和LMR，分析炎症指标与其他临床病理特征及淋巴结转移的关系。
■有淋巴结转移的PTC患者303例（55.4%）。SII的水平，SIRI,NLR,有淋巴结转移的患者PLR明显高于无淋巴结转移的患者,而LMR水平明显低于无淋巴结转移患者（均p<0.05）。以淋巴结转移为终点，SII临界值为625.375,SIRI临界值为0.705,NLR临界值为1.915(ROC曲线下面积均>0.6).Logistic回归分析结果显示,年龄<55岁(OR:1.626,95%CI:1.009~2.623,p=0.046),肿瘤最大直径>1cm(OR:2.681,95%CI:1.819-3.952,p<0.001),BRAFV600E突变(OR:2.709,95%CI:1.542-4.759,p=0.001),SII阳性（≥625.375/<625.375，OR：2.663，95％CI：1.560-4.546，p<0.001），NLR阳性(≥1.915/<1.915,OR:1.808,95%CI:1.118~2.923,p=0.016)是PTC淋巴结转移的独立危险因素。
■年龄<55岁，肿瘤最大直径>1cm,BRAFV600E突变,SII阳性，NLR阳性是PTC淋巴结转移的独立危险因素。
■回顾性分析2018年1月至2021年12月梅州市人民医院收治的547例PTC患者。收集临床病理资料,包括性别,年龄,桥本甲状腺炎,肿瘤最大直径,膜外渗透,疾病阶段,BRAFV600E突变,治疗前炎症指数水平，淋巴结转移。SII的最佳截止值，SIRI,NLR,通过受试者工作特征（ROC）曲线计算PLR和LMR，分析炎症指标与其他临床病理特征及淋巴结转移的关系。
■有淋巴结转移的PTC患者303例（55.4%）。SII的水平，SIRI,NLR,有淋巴结转移的患者PLR明显高于无淋巴结转移的患者,而LMR水平明显低于无淋巴结转移患者（均p<0.05）。以淋巴结转移为终点，SII临界值为625.375,SIRI临界值为0.705,NLR临界值为1.915(ROC曲线下面积均>0.6).Logistic回归分析结果显示,年龄<55岁(OR:1.626,95%CI:1.009~2.623,p=0.046),肿瘤最大直径>1cm(OR:2.681,95%CI:1.819-3.952,p<0.001),BRAFV600E突变(OR:2.709,95%CI:1.542-4.759,p=0.001),SII阳性（≥625.375/<625.375，OR：2.663，95％CI：1.560-4.546，p<0.001），NLR阳性(≥1.915/<1.915,OR:1.808,95%CI:1.118~2.923,p=0.016)是PTC淋巴结转移的独立危险因素。
■年龄<55岁，肿瘤最大直径>1cm,BRAFV600E突变,SII阳性，NLR阳性是PTC淋巴结转移的独立危险因素。
